Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial-MedSci.cn

Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial

Weiskittel, T; McDermott, J; Billadeau, D; Li, H; Saeed, A; Mahalingam, D; Sahebjam, S; Munster, P; Cavalcante, L; Giles, FJ; Mazar, A; Carneiro, B

CANCER RESEARCH, 2023; 83 (8):

科室
- - 订阅+
  - 更多科室
工具
服务